A variable pattern of response was also seen with orforglipron in the obesity trial, with NT-pro-BNP changes in individual treatment groups ranging from + 1.9 to − 19.5% (Fig. 4, Supplemental Table 2). This evidence concerns the gene NPPB and Obesity.